Home Blog Page 4

Bitcoin Dips below $65,000 as Strong US Manufacturing Data Bolsters Dollar, Shaking Crypto Markets

0

In the recent trading session on Tuesday, Bitcoin experienced a downturn as positive manufacturing data from the United States boosted the dollar, reaching its peak level since mid-November. The premiere digital currency saw a decrease of 4%, dropping to $66,342, marking an end to its week-long stable phase that fluctuated between $68,000 and $72,000, according to figures from CoinDesk. This downturn was part of a broader trend in the cryptocurrency market, where other major digital currencies such as Ethereum, Solana’s SOL, and Dogecoin also faced notable declines. Specifically, the CoinDesk 20, which encapsulates a broader range of cryptocurrencies, recorded a nearly 8% fall.

The surge in the dollar’s value, as depicted by the dollar index (DXY) surpassing 105 — a first in over four months, with a cumulative four-week increase of 2.58%, significantly influenced the market. The appreciation of the dollar generally results in making assets priced in dollars, like Bitcoin and gold, more costly, which can suppress demand. Moreover, a persistently strong dollar can lead to tighter financial conditions globally, reducing the appetite for risk among investors. This sentiment was further reinforced by the unexpected expansion in manufacturing activity in March, as reported by the Institute for Supply Management’s (ISM) manufacturing purchasing managers’ index (PMI). The PMI climbed 2.5 points to 50.3, indicating the first expansion since September 2022 and breaking a 16-month streak of contraction. This shift not only suggests less likelihood of Federal Reserve rate reductions but also indicates a possible reticence from the Fed regarding aggressive monetary easing, given the market’s response to the manufacturing data and anticipated inflation pressures.

Furthermore, the Bloomberg report indicating a reduction in the market’s expectations for Federal Reserve rate cuts to less than 65 basis points for the year, following the manufacturing report, underscores the recalibration of monetary policy expectations. The anticipated timeline for Fed rate cuts, particularly the forecast for a June adjustment, now falls below a 50% probability.

Analysts, particularly those from ING, have highlighted the market’s keen focus on the ISM report. The return of growth in the manufacturing sector and associated inflation readings have led to a rise in 10-year Treasury yields by 10 basis points. With around 20 Federal Reserve officials scheduled to speak throughout the week, the prevailing sentiment is one of caution against promising substantial policy easing, given the current economic indicators.

Altimmune (NASDAQ: ALT) Announces Promising Obesity Treatment Results and Strategic Focus Shifts: A Closer Look for Investors”

0

In a significant update that has captivated the biopharmaceutical sector, Altimmune, Inc. (Nasdaq: ALT) has unveiled its financial achievements for the fourth quarter and the entirety of 2023, alongside a pivotal business progress report. The clinical-stage company, known for its innovative approach to addressing critical healthcare needs, shared insights into its latest clinical trial results and strategic decisions that have the industry buzzing.

At the heart of Altimmune’s recent triumphs is pemvidutide, its groundbreaking candidate in the fight against obesity. Dr. Vipin K. Garg, Ph.D., Altimmune’s President and CEO, expressed his enthusiasm over the MOMENTUM trial’s outcomes, highlighting that a staggering 74.5% of the weight loss achieved was from adipose tissue, with only a minimal impact on lean mass. This balance is not just promising; it’s revolutionary, aligning closely with the desirable outcomes of traditional weight loss methods like diet and exercise. The trial not only underscored pemvidutide’s effectiveness but also its safety and potential to significantly reduce serum lipids and blood pressure.

The momentum for pemvidutide doesn’t stop there. With its positive top-line data from the 48-week Phase 2 obesity trial revealing an average weight loss of 15.6% at the optimal dose and notable improvements in cholesterol levels and liver health, pemvidutide is shaping up to be a standout treatment option. Furthermore, the ongoing IMPACT Phase 2b MASH trial, buoyed by FDA Fast Track designation, is set to deliver key findings in early 2025, potentially cementing pemvidutide’s status in treating metabolic and liver diseases.

However, not all journeys lead to their expected destinations. The development of HepTcell, aimed at combating chronic hepatitis B, has been halted following insufficient trial results. This decision reflects Altimmune’s commitment to focusing its resources on the most promising avenues of research.

From a financial standpoint, Altimmune is positioned strongly with $198.0 million in cash reserves as of the end of 2023. While research and development expenses have seen slight fluctuations, the company’s strategic investments, particularly in pemvidutide, underscore its dedication to bringing transformative treatments to market. Despite recognizing a significant impairment loss on the HepTcell asset, Altimmune’s forward-looking approach and promising pipeline suggest a bright future.

For traders and investors, Altimmune’s latest update presents a nuanced picture of opportunity and strategic realignment. The potential market impact of pemvidutide as a leading obesity and metabolic disease therapy could signify a significant shift in the biopharmaceutical landscape. As Altimmune progresses with its clinical trials and refines its focus, the financial community will undoubtedly watch closely, eager to participate in the company’s journey towards redefining treatment paradigms in critical healthcare areas.

The stock closed over 10$ in the previous session. The stock’s price fluctuated between $8.84 and $10.50 throughout the day. Over the past 52 weeks, the stock has seen a low of $2.09 and a high of $14.84. Today’s trading volume reached 8,496,171, surpassing the average volume of 6,066,418.

Surge in Penny Stock Trading: Lucid Secures $1B Investment and Esperion Presents at ACC.24 (LCID, NKLA, WULF, OPK, ESPR)

0

Today’s trading session has seen a significant surge in activity among penny stocks, with particular attention on companies such as Lucid Group, Inc., Nikola Corporation, TeraWulf Inc., OPKO Health, Inc., and Esperion Therapeutics, Inc. These companies have not only experienced notable changes in their stock values but have also seen remarkable trading volumes, indicating a strong interest from investors looking for potential opportunities in the lower-priced segment of the market.

Leading the activity, Lucid Group, Inc. (LCID) observed its stock rise to $2.92, a 5.42% increase, with an impressive trading volume of 104.45 million shares. This significant movement came after the electric vehicle maker announced it had secured a $1 billion investment from an affiliate of the Public Investment Fund, Saudi Arabia’s sovereign wealth fund. This strategic financial boost is expected to enhance Lucid’s position in the EV market, thereby attracting more attention and investment into its stock.

Not too far behind in terms of investor interest, Nikola Corporation (NKLA) saw its stock price ascend by 12.28% to $0.7436, with a trading volume of 165.77 million shares. This surge in activity suggests a growing interest or speculative investment in Nikola’s innovative business model and its potential for future growth.

In the realm of environmentally sustainable technologies, TeraWulf Inc. (WULF) made notable gains by increasing 4.47% to $2.57 on a trading volume of 31.54 million shares. This movement underscores the escalating interest among investors in green technology and TeraWulf’s endeavors in sustainable cryptocurrency mining.

In the healthcare sector, OPKO Health, Inc. (OPK) experienced a 4.71% increase in its stock price to $1.01, with 29.85 million shares traded. This above-average volume indicates a heightened focus on OPKO’s innovative medical solutions and potential market impact.

Esperion Therapeutics, Inc. (ESPR), specializing in lipid management therapies, witnessed a significant uptick of 14.41% to $2.62, supported by a trading volume of 27.46 million shares. This increase in interest comes on the heels of a recent announcement from Esperion. On March 25, 2024, Esperion disclosed the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at the 2024 American College of Cardiology’s Annual Scientific Session (ACC.24) in Atlanta, Georgia. In addition to these presentations, the company will engage in a moderated session in collaboration with UT Southwestern Medical Center, host an industry expert theatre, and maintain a commercial and medical information booth throughout the event.

JoAnne Foody, MD, Chief Medical Officer for Esperion, expressed enthusiasm for the company’s participation in ACC.24, emphasizing their commitment to cardiovascular care for all, especially underserved populations. The presentations will focus on subset analyses in women and Hispanic/Latinx patients, as well as patients with obesity, aligning with the conference’s theme and showcasing Esperion’s dedication to broadening the impact of its pivotal CLEAR Outcomes trial.

Today’s active penny stock market highlights the dynamic and often volatile nature of this investment sector, where company announcements, investor sentiment, and market trends can quickly alter the landscape, offering both opportunities and challenges for investors eager to navigate the complexities of penny stocks.

Bitcoin and Crypto Markets Face Turbulence: Prices Dip Amid ETF Outflows and Macro Challenges

0

Crypto markets experienced another day of significant volatility this Friday, with Bitcoin (BTC) momentarily dipping below the $63,000 threshold from a higher position around $67,000 just a few hours before. A slight recovery has since occurred, bringing Bitcoin’s price to approximately $64,000, marking a 3.7% decline over the last day.

This downward trend extended across the cryptocurrency market, as evidenced by the 4.4% drop in the broad CoinDesk 20 Index during the same period. The downturn was notably led by a more than 10% decrease in Solana’s token (SOL) at certain points.

The market correction phase that began over a week ago, following Bitcoin’s retreat from a new all-time high above $73,000, persists. Despite a hopeful 10% surge on Wednesday, propelled by a dovish stance from the Federal Reserve, the anticipated quick market recovery has yet to materialize. Mike Novogratz, the CEO of Galaxy Digital, remarked during a Bitcoin Investor Day panel in New York, “It will take some time before we take out that $73,000 again.”

This period of sluggish market performance coincides with a streak of net negative flows for U.S.-listed spot Bitcoin ETFs, marking four consecutive days of losses. Although most funds continue to attract new investments, the inflows have been insufficient to counteract significant withdrawals from the Grayscale Bitcoin Trust (GBTC), which saw $359 million in outflows on Thursday alone, contributing to a total of $94 million in outflows for the group. Furthermore, Fidelity’s Wise Origin Bitcoin Fund (FBTC) recorded its lowest daily inflow, according to data from BitMEX Research.

Over the week, spot ETFs have witnessed over $830 million in outflows, approaching their second negative week since a downturn in late January when BTC prices fell to $39,000.

Coinbase Institutional analysts have suggested that the spike in GBTC sell-offs might be partly attributed to Genesis offloading shares as part of its bankruptcy proceedings. They anticipate that once these sales conclude, ETF inflows might rebound, supported by favorable macroeconomic conditions and central bank policies. The Coinbase report optimistically states, “We think the macro environment remains conducive to more spot bitcoin ETF inflows following the Federal Reserve meeting on March 20. We expect the current US disinflationary trend to persist, US financial conditions to keep improving, and market conditions to be buoyed by the Fed scaling back its quantitative tightening program.”

BlackRock Dives Deeper into Crypto: Launches Bitcoin Fund and Explores Ethereum Amidst Investor Interest

0

During a recent discussion at the Bitcoin Investor Day event held in New York, Robert Mitchnick, the lead for digital asset strategies at the renowned investment firm BlackRock, shared insights into the firm’s clientele’s interest in cryptocurrencies. Mitchnick highlighted that Bitcoin remains the primary interest among their clients, with Ethereum garnering modest attention in comparison. “Bitcoin definitely holds the spotlight for our investors, with Ethereum catching interest to a lesser extent,” Mitchnick remarked during the event.

The conversation also veered towards the topic of BlackRock potentially launching an exchange-traded fund (ETF) focused on the meme-inspired cryptocurrency dogwifhat (WIF). Mitchnick admitted to being unfamiliar with the asset, emphasizing a common misperception within the crypto community about BlackRock’s ambitions to extend a wide array of services in the sector. “Our main focus doesn’t align with such offerings,” he clarified.

January marked a significant moment for BlackRock in the realm of digital assets, as it received approval to introduce the Bitcoin Bitcoin Fund (IBIT) to its investors. This fund quickly ascended to become one of the top five ETFs in the market within just two months, amassing $15 billion in assets, a figure that surpasses the combined assets of the other nine funds in its category. Mitchnick attributed the decision to launch a Bitcoin ETF to the consistent interest and demand from clients for Bitcoin investment opportunities across various market conditions.

He also shared the challenges clients faced in gaining access to cryptocurrencies, expressing their “frustration” with the complexities involved. Adding to its innovative offerings, BlackRock recently announced the launch of its tokenized asset fund, BUIDL, which operates on the Ethereum network. This initiative is facilitated through a partnership with Securitize, a firm specializing in asset tokenization, which serves as both a transfer agent and platform for tokenization.

Boeing Co (NYSE:BA) stock could surprise investors in 2023

0

Boeing Co (NYSE:BA) last traded at $189.06 and could be an exciting stock to add to ones portfolio in 2023. Everything is coming together for the aerospace giant and here’s why. Aerospace is a long-cycle industry and 2023 is very early days in a new cycle, with multiple years of strong growth from a low starting point still to come.

BA Stock

Shares are up about 40% over the past six months, and they have more room to run in 2023 as travel picks up pace post pandemic. Global air travel has largely recovered, airlines are placing orders for new planes at a near-record pace, the MAX and 787 are delivering and production rates are ramping, and China is de-risked from the MAX skyline.

Is Bitcoin ready to recover the 60% decline in bitcoin in 2022

0

Bitcoin has fallen more than 60% this year and sits roughly 75% off of its all-time high from November 2021. The steepest one-time drops this year followed the big Terra and FTX scandals, but crypto prices are still largely driven by the macro picture, analysts say.

Also, cryptocurrency prices, have remained relatively stable since the summer. Prices have been trading sideways, but some think most of the carnage in the market is done and that while they could still fall, they’ve been at or close to the bottom.

Lyn Alden, founder of Lyn Alden Investment Strategy, said these beaten down levels are a good accumulation point for someone with a three-year view or longer on bitcoin, but they “have to be concerned” in the near term.

In 2023, earnings are more of the concern for the broader asset space but the overall hardness of the dollar and reduction valuations of some is not going to be the big story. This could gives assets like gold or bitcoin a chance to potentially do better than what we see in in the broad equity space because the weakness is probably going to be more earnings related.

Meta Platform (NASDAQ:META) in trouble again with European Commission

0

Tech Stocks are in deep trouble as most of them have shed YTD gains. Meta Platform (NASDAQ:META) could see further sell off after the European Commission accused the Facebook parent of violating the EU’s antitrust laws. The EU also said the social media giant could face possible changes to its business practices or be fined up to 10% of its global annual revenue if the commission finds sufficient evidence of a violation.

META Stock Chart

Shares of Meta and Microsoft are both held in Jim Cramer’s Charitable Trust portfolio. Economic challenges across the world, combined with pressures on Meta’s core business has created a perfect storm of skepticism about the investments

Chinese Stocks could rebound hard in 2023 and here’s why

0

Investors have cheered the relaxation of restrictions. China’s CSI 300 index, which tracks the largest mainland-listed stocks, has risen 5.8% since China announced a reduction in the quarantine period for travelers on Nov. 10. Hong Kong’s Hang Seng index
is up 18.9% over the same period.

And it’s not just the reopening that is driving market optimism. China has, in recent months, announced a slew of measures in an effort to arrest the country’s worst property slump in decades, raising hopes of a turnaround in the beleaguered sector.

Wall Street is taking notice. Morgan Stanley
turned bullish on China stocks for the first time in nearly two years, upgrading China to overweight versus emerging market stocks on Dec. 4 as the country embarks on a “clear path set towards reopening.”

Middle East’s Largest Crypto Exchange Rain Financial Inc Announces Layoffs Amid Crypto Slump 

0

According to recent studies, even one tiny wine glass each day may trigger Parkinson’s or Alzheimer’s disease development.

Alcohol consumption linked to cognitive decline 

According to University of Oxford investigators, about seven pints of beer per week, or half the advised limit, is enough to drive iron buildup in the brain. They explain that alcohol impairs brain function by suppressing a hormone that regulates mineral absorption in the body.

Lead study author Dr. Anya Topiwala said, “In the largest study to date, we found drinking greater than 7 units of alcohol weekly associated with iron accumulation in the brain. Higher brain iron in turn linked to poorer cognitive performance. Iron accumulation could underlie alcohol-related cognitive decline.” 

 In Dementia patients, scientists have discovered an area with greater iron overload, which includes the deep grey matter. Also, in Parkinson’s disease, a similar pattern has been established. 

Injurious plaques made of amyloid beta, a renegade protein that clumps together and kills neurons, have been linked in trials to cognitive loss. Blood-borne iron is necessary for proper brain activity, but it must be strictly controlled.

The 21,000-person study provides more proof that even moderate alcohol consumption can influence brain health. Alcohol use of seven units or greater per week was linked to basal ganglia indications of increased iron levels. These neural networks regulate various functions, including cognition, eye movement, emotion, and motor activity. Poorer mental abilities are associated with iron build-up in some brain regions.

Alcohol consumption reduces brain iron levels 

Alcohol reduces iron levels in the brain, called chelators that have been widely studied as possible Parkinson’s and Alzheimer’s disease treatment. Higher circulating iron levels could partially influence alcohol-related brain iron, although it is probable that there are other processes at play as well. There were indications of greater basal ganglia iron, worse cognitive function, fluid intelligence, and slower reaction times.

 According to the study authors, brain iron buildup could be a potential trigger of alcohol-linked cognitive decline. As a result, the CDC recommends taking no more than two drinks a day.